Selecting multimodal therapy for rhabdomyosarcoma
- 1 August 2010
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Anticancer Therapy
- Vol. 10 (8), 1285-1301
- https://doi.org/10.1586/era.10.96
Abstract
Rhabdomyosarcoma is a typical tumor of childhood, characterized by a high grade of malignancy, local invasiveness and a marked propensity to metastasize, but also a generally good response to chemotherapy and radiotherapy. Multimodal therapy is essential to cure rhabdomyosarcoma patients, but different uses of surgery, radiotherapy and chemotherapy, and their intensity, need to be selected and modulated to different patient risk groups. This article attempts to give an account of the current treatment options, the open and debated issues and the potential novel strategies for the near future.Keywords
This publication has 98 references indexed in Scilit:
- Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: A Children's Oncology Group studyPediatric Blood & Cancer, 2009
- Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumorsCancer, 2009
- Revisiting the role of doxorubicin in the treatment of rhabdomyosarcoma: An up-front window study in newly diagnosed children with high-risk metastatic diseaseEuropean Journal of Cancer, 2008
- Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinibMolecular Cancer Therapeutics, 2008
- Cyclophosphamide Dose Intensification during Induction Therapy for Intermediate-Risk Pediatric Rhabdomyosarcoma Is Feasible but Does Not Improve OutcomeClinical Cancer Research, 2004
- European collaboration in trials of new agents for children with cancerEuropean Journal of Cancer, 2004
- A novel local treatment strategy for advanced stage head and neck rhabdomyosarcomas in children: results of the AMORE protocolEuropean Journal of Cancer, 2003
- Survival of children with soft-tissue sarcoma in Europe since 1978: results from the EUROCARE studyEuropean Journal of Cancer, 2001
- The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment ProtocolsSarcoma, 2001
- Vinca alkaloids: Anti-vascular effects in a murine tumourEuropean Journal of Cancer, 1993